ArticleExpert review of anticancer therapy2017

A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1).

Raffaele AddeoPubMed ↗Publisher ↗

No numbers read from the abstract.